Abstract 1648P
Background
Cancer patients have a risk up to nine times higher of suffering from venous thromboembolism (VTE) compared to those without cancer, which makes VTE the second preventable cause of mortality in cancer patients. Pancreatic carcinoma is a high thrombotic risk tumor, being its incidence of thrombosis of up to 30% in outpatient patients. It has been suggested that circulating tumor cells (CTC) may be related to thrombosis, as they can alter blood coagulation and due to their pro-inflammatory and pro-coagulant properties.
Methods
We conducted an observational, prospective, cohort study in a two Spanish centers. CTC were isolated from a blood sample of newly diagnosed patients of pancreas carcinoma before starting chemotherapy treatment. CTC count was determined by using Isoflux® technology followed by counting via confocal microscopy. Patients were followed up according to routine practice. Clinical and analytical data were collected up to death. We analyzed the relation between CTC and VTE, and between CTC and VTE scores.
Results
This analysis included a total of 63 patients newly diagnosed before chemotherapy was given. 39 (61,9%) patients were metastatic, 16 (25,4%) locally advanced and 8 (12,7%) borderline tumors. Median follow up was 11,63 months. 25 episodes of VTE occurred in 23 patients during follow up (11 pulmonary embolism, 5 deep vein thrombosis, 6 visceral thrombosis, 3 catheter-related thrombosis). Median value of CTC was 397 (range 33-21697). For a cut off of CTC 500, we found no relation between CTC and VTE (p=0,298). However, when we analyzed CTC>500 and VTE excluding visceral and catheter-related thrombosis, it was found to be associated (p=0.006, p=0.002 in those metastatic). We found no relation between CTC and thrombosis scores (Khorana, Viena, Protech, Conko nor CAT).
Conclusions
This study shows that CTC detection before first-line chemotherapy could be a predictor marker for VTE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fundacion Investigación Biomedica Gregorio Marañon.
Funding
Fundación Investigación Biomedica Gregorio Marañon.
Disclosure
P. García Alfonso: Financial Interests, Personal, Advisory Board: Amgen. M. Martin Jimenez: Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly, Roche/Genentech, Daiichi Sankyo, Menarini-Stemline; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Lilly, Novartis, Roche/Genentech; Financial Interests, Institutional, Research Grant: Novartis, Roche, Puma; Non-Financial Interests, Member of Board of Directors: TRIO; Non-Financial Interests, Leadership Role: GEICAM; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Advisory Board: Seom. All other authors have declared no conflicts of interest.
Resources from the same session
1589P - Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin
Presenter: Niels Guchelaar
Session: Poster session 22
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22